

SUMMARY OF THE PROPOSED TRANSACTION

[In terms of Regulation 13 (1B) of the Competition Commission of India (Procedure in regard to the transaction of business relating to combinations), 2011, as amended (**Combination Regulations**)]

1. Name of the parties

The parties are ICU Medical, Inc. ("**ICU**") and Pfizer, Inc. ("**Pfizer**", and together with ICU, "**Parties**")

2. Type of combination

The Proposed Combination is in the nature of an acquisition within the meaning of Section 5(a)(i)(A) of the Competition Act, 2002.

ICU proposes to acquire Pfizer's Hospira Infusions Systems business (**HIS Business**) comprising of manufacture and sale of medical devices used in infusion therapy.

3. Area of activity of the Parties

ICU is active in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications.

Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines in areas including primary care, specialty care,

oncology, consumer healthcare. Pfizer is also active in medication management which comprises products used in infusion systems.

4. Relevant markets

The relevant market, for the purposes of the Proposed Combination is the market for infusion therapy devices and closed systems for preparing and administering drugs in India.